Regeneron's Andrew Murphy Executes Stock Option and Sells Shares Under 10b5-1 Plan on October 14
Alpha Vantage · Kalkine Media · · AI-summarised by FinFlash
Andrew J. Murphy, Co-Chief Scientific Officer at Regeneron Pharmaceuticals, Inc., exercised stock options and sold common stock on October 13 and 14, 2026, under a Rule 10b5-1 trading plan. The transactions involved exercising options for 17,000 shares, withholding 12,853 shares for tax, and selling an additional 4,068 shares on the open market.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.